These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 6883952)

  • 1. Is canrenone the major metabolite of spironolactone?
    Merkus FW
    Clin Pharm; 1983; 2(3):209-10. PubMed ID: 6883952
    [No Abstract]   [Full Text] [Related]  

  • 2. Application of a simple fluorometric method on absorption of canrenone.
    Radó JP; Szende L; Takó J; Nagy O; Kozma C
    Int J Clin Pharmacol Biopharm; 1976 Mar; 13(2):123-6. PubMed ID: 1254376
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Aspects of the physiologic bioavailability of spironolactone and canrenone].
    Portal A; Gaillot J; Bieder A; Rodary C; Bertharion JJ
    Sem Hop Ther; 1976 Nov; 52(9):465-70. PubMed ID: 1006321
    [No Abstract]   [Full Text] [Related]  

  • 4. The influence of age and multimorbidity on the pharmacokinetics and metabolism of spironolactone.
    Platt D; Abshagen U; Mühlberg W; Horn HJ; Schmitt-Rüth R; Vollmar J
    Arch Gerontol Geriatr; 1984 Jul; 3(2):147-59. PubMed ID: 6476975
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of canrenone and metabolites after base hydrolysis following single and multiple dose oral administration of spironolactone.
    Ho PC; Bourne DW; Triggs EJ; Heazlewood V
    Eur J Clin Pharmacol; 1984; 27(4):441-6. PubMed ID: 6519151
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-performance liquid chromatographic determination of canrenone, a major metabolite of spironolactone, in body fluids.
    Neurath GB; Ambrosius D
    J Chromatogr; 1979 Jun; 163(2):230-5. PubMed ID: 541378
    [No Abstract]   [Full Text] [Related]  

  • 7. Validation of plasma and urinary canrenone for determination of bioavailability of spironolactone--comparison of tablets with solution/suspension.
    Tidd MJ; Ramsay LE; Shelton JR; Palmer RF
    Int J Clin Pharmacol Biopharm; 1977 May; 15(5):205-10. PubMed ID: 873663
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of canrenone after oral administration of spironolactone and intravenous injection of canrenoate-K in healthy man.
    Krause W; Karras J; Seifert W
    Eur J Clin Pharmacol; 1983; 25(4):449-53. PubMed ID: 6653638
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhancement by food of canrenone bioavailability from spironolactone.
    Melander A; Danielson K; Scherstén B; Thulin T; Wåhlin E
    Clin Pharmacol Ther; 1977 Jul; 22(1):100-3. PubMed ID: 872489
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Determination of canrenone, the major metabolite of spironolactone, in plasma and urine by high-performance liquid chromatography.
    Krause W; Karras J; Jakobs U
    J Chromatogr; 1983 Oct; 277():191-9. PubMed ID: 6643605
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ring D oxygenated Spirolactones. Characterization of human metabolic product of spironolactone.
    Chinn LJ; Brown EA; Mizuba SS; Karim A
    J Med Chem; 1977 Mar; 20(3):352-5. PubMed ID: 845867
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Re-evaluation of the antimineralocorticoid effect of the spironolactone metabolite, canrenone, from plasma concentrations determined by a new high-pressure liquid-chromatographic method.
    Dahlöf CG; Lundborg P; Persson BA; Regårdh CG
    Drug Metab Dispos; 1979; 7(2):103-7. PubMed ID: 38071
    [No Abstract]   [Full Text] [Related]  

  • 13. Pharmacokinetics of spironolactone after a single dose: evaluation of the true canrenone serum concentrations during 24 hours.
    Merkus FW; Overdiek JW; Cilissen J; Zuidema J
    Clin Exp Hypertens A; 1983; 5(2):239-48. PubMed ID: 6831747
    [No Abstract]   [Full Text] [Related]  

  • 14. Spironolactone response related to plasma canrenone concentration [proceedings].
    Hettiarachchi J; Ramsay LE
    Br J Clin Pharmacol; 1979 Apr; 7(4):426P-427P. PubMed ID: 444376
    [No Abstract]   [Full Text] [Related]  

  • 15. Biotransformations of the cardiovascular drugs mexrenone and canrenone.
    Preisig CL; Laakso JA; Mocek UM; Wang PT; Baez J; Byng G
    J Nat Prod; 2003 Mar; 66(3):350-6. PubMed ID: 12662091
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Pharmacokinetic studies and bioavailability of bendroflumethiazide in combination with spironolactone].
    Vergin H; Nuss U; Strobel K
    Arzneimittelforschung; 1986 Mar; 36(3):490-5. PubMed ID: 3707669
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development and validation of an HPLC method for the determination of spironolactone and its metabolites in paediatric plasma samples.
    Sandall JM; Millership JS; Collier PS; McElnay JC
    J Chromatogr B Analyt Technol Biomed Life Sci; 2006 Jul; 839(1-2):36-44. PubMed ID: 16510319
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Spironolactone. III. Canrenone--maximum and minimum steady-state plasma levels.
    Karim A; Zagarella J; Hutsell TC; Dooley M
    Clin Pharmacol Ther; 1976 Feb; 19(2):177-82. PubMed ID: 1261155
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Simultaneous determination of spironolactone and its active metabolite canrenone in human plasma by HPLC-APCI-MS.
    Dong H; Xu F; Zhang Z; Tian Y; Chen Y
    J Mass Spectrom; 2006 Apr; 41(4):477-86. PubMed ID: 16541392
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Abbott ARCHITECT clinical chemistry and immunoassay systems: digoxin assays are free of interferences from spironolactone, potassium canrenoate, and their common metabolite canrenone.
    DeFrance A; Armbruster D; Petty D; Cooper KC; Dasgupta A
    Ther Drug Monit; 2011 Feb; 33(1):128-31. PubMed ID: 21079546
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.